Hirsutism surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either [[ovarian tumor]], [[adrenal tumor]], or perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] who are candidated for [[oophorectomy]]. | The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either [[ovarian tumor]], [[adrenal tumor]], or perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] who are candidated for [[oophorectomy]]. | ||
==Surgery== | ==Surgery== | ||
{| align="right" | |||
| {{#ev:youtube|PF2LH6CuesY|500}} | |||
|} | |||
*The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either: | *The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either: | ||
**[[Ovarian tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | **[[Ovarian tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | ||
**[[Adrenal tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | **[[Adrenal tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | ||
**Perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] are candidated for [[oophorectomy]]<ref name="pmid24728167">{{cite journal| author=Souto SB, Baptista PV, Braga DC, Carvalho D| title=Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism. | journal=Arq Bras Endocrinol Metabol | year= 2014 | volume= 58 | issue= 1 | pages= 68-75 | pmid=24728167 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24728167 }} </ref><ref name="pmid20198556">{{cite journal| author=Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B et al.| title=Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. | journal=Exp Clin Endocrinol Diabetes | year= 2010 | volume= 118 | issue= 5 | pages= 291-7 | pmid=20198556 | doi=10.1055/s-0029-1225351 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20198556 }} </ref> | **Perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] are candidated for [[oophorectomy]]<ref name="pmid24728167">{{cite journal| author=Souto SB, Baptista PV, Braga DC, Carvalho D| title=Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism. | journal=Arq Bras Endocrinol Metabol | year= 2014 | volume= 58 | issue= 1 | pages= 68-75 | pmid=24728167 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24728167 }} </ref><ref name="pmid20198556">{{cite journal| author=Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B et al.| title=Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. | journal=Exp Clin Endocrinol Diabetes | year= 2010 | volume= 118 | issue= 5 | pages= 291-7 | pmid=20198556 | doi=10.1055/s-0029-1225351 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20198556 }} </ref> | ||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 16:30, 10 October 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism surgery On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2], Rasam Hajiannasab M.D.[3]
Overview
The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either ovarian tumor, adrenal tumor, or perimenopausal or postmenopausal women with severe hyperandrogenism who are candidated for oophorectomy.
Surgery
| PF2LH6CuesY|500}} |
- The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either:
- Ovarian tumor[1]
- Adrenal tumor[1]
- Perimenopausal or postmenopausal women with severe hyperandrogenism are candidated for oophorectomy[2][3]
References
- ↑ 1.0 1.1 Franks, Stephen (2012). "The investigation and management of hirsutism". Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.
- ↑ Souto SB, Baptista PV, Braga DC, Carvalho D (2014). "Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism". Arq Bras Endocrinol Metabol. 58 (1): 68–75. PMID 24728167.
- ↑ Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B; et al. (2010). "Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature". Exp Clin Endocrinol Diabetes. 118 (5): 291–7. doi:10.1055/s-0029-1225351. PMID 20198556.